JP7863883B2 - 呼吸器ウイルスに対する汎遺伝子型薬剤及びそれを使用する方法 - Google Patents

呼吸器ウイルスに対する汎遺伝子型薬剤及びそれを使用する方法

Info

Publication number
JP7863883B2
JP7863883B2 JP2022548912A JP2022548912A JP7863883B2 JP 7863883 B2 JP7863883 B2 JP 7863883B2 JP 2022548912 A JP2022548912 A JP 2022548912A JP 2022548912 A JP2022548912 A JP 2022548912A JP 7863883 B2 JP7863883 B2 JP 7863883B2
Authority
JP
Japan
Prior art keywords
sequence
seq
oligonucleotide
nucleotides
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022548912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514576A (ja
JP2023514576A5 (enExample
Inventor
ジェフリー エス． グレン，
レイチェル ヘイギー サルティ，
エドワード エー． パム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/792,103 external-priority patent/US11339392B2/en
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2023514576A publication Critical patent/JP2023514576A/ja
Publication of JP2023514576A5 publication Critical patent/JP2023514576A5/ja
Priority to JP2026000520A priority Critical patent/JP2026042885A/ja
Application granted granted Critical
Publication of JP7863883B2 publication Critical patent/JP7863883B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022548912A 2020-02-14 2021-02-12 呼吸器ウイルスに対する汎遺伝子型薬剤及びそれを使用する方法 Active JP7863883B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026000520A JP2026042885A (ja) 2020-02-14 2026-01-05 呼吸器ウイルスに対する汎遺伝子型薬剤及びそれを使用する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16/792,103 2020-02-14
US16/792,103 US11339392B2 (en) 2016-03-02 2020-02-14 Pan-genotypic agents against influenza virus and methods of using the same
US202062992659P 2020-03-20 2020-03-20
US62/992,659 2020-03-20
PCT/US2021/018025 WO2021201996A1 (en) 2020-02-14 2021-02-12 Pan-genotypic agents against respiratory viruses and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026000520A Division JP2026042885A (ja) 2020-02-14 2026-01-05 呼吸器ウイルスに対する汎遺伝子型薬剤及びそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2023514576A JP2023514576A (ja) 2023-04-06
JP2023514576A5 JP2023514576A5 (enExample) 2024-05-16
JP7863883B2 true JP7863883B2 (ja) 2026-05-22

Family

ID=77929340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548912A Active JP7863883B2 (ja) 2020-02-14 2021-02-12 呼吸器ウイルスに対する汎遺伝子型薬剤及びそれを使用する方法

Country Status (2)

Country Link
JP (1) JP7863883B2 (enExample)
WO (1) WO2021201996A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021177773A2 (ko) * 2020-03-06 2021-09-10 (주)지노믹트리 Sars-cov-2 진단용 조성물, 키트 및 이를 이용한 sars-cov-2의 진단방법
CN115976271B (zh) * 2021-10-14 2025-04-25 深圳华大智造科技股份有限公司 流感与新型冠状病毒全基因组共扩增引物池及其建库方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
JP2009532392A (ja) 2006-04-03 2009-09-10 サンタリス ファーマ アー／エス ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
WO2013166264A2 (en) 2012-05-02 2013-11-07 University Of Georgia Research Foundation, Inc. Methods for altering virus replication

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US8357664B2 (en) * 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
CA2603842A1 (en) * 2005-04-08 2006-10-19 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
US20090042823A1 (en) * 2007-08-10 2009-02-12 Mdrna, Inc. Uses of broad spectrum rnai therapeutics against influenza
US10597658B2 (en) * 2016-03-02 2020-03-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
JP2009532392A (ja) 2006-04-03 2009-09-10 サンタリス ファーマ アー／エス ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
WO2013166264A2 (en) 2012-05-02 2013-11-07 University Of Georgia Research Foundation, Inc. Methods for altering virus replication

Also Published As

Publication number Publication date
WO2021201996A1 (en) 2021-10-07
JP2023514576A (ja) 2023-04-06

Similar Documents

Publication Publication Date Title
Limburg et al. TMPRSS2 is the major activating protease of influenza A virus in primary human airway cells and influenza B virus in human type II pneumocytes
JP2022176378A (ja) インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
Lee et al. A nucleic-acid hydrolyzing single chain antibody confers resistance to DNA virus infection in hela cells and C57BL/6 mice
Abdelwhab et al. Prevalence of the C-terminal truncations of NS1 in avian influenza A viruses and effect on virulence and replication of a highly pathogenic H7N1 virus in chickens
JP2023514576A (ja) 呼吸器ウイルスに対する汎遺伝子型薬剤及びそれを使用する方法
US12522827B2 (en) Pan-genotypic agents against influenza virus and methods of using the same
CN101880677B (zh) 针对2009新甲型流感病毒多聚酶基因和核蛋白基因的siRNA序列及其应用
Guo et al. Integrated analysis of microRNA-mRNA expression in mouse lungs infected with H7N9 influenza virus: a direct comparison of host-adapting PB2 mutants
Giannecchini et al. Oligonucleotides derived from the packaging signal at the 5′ end of the viral PB2 segment specifically inhibit influenza virus in vitro
JP2026042885A (ja) 呼吸器ウイルスに対する汎遺伝子型薬剤及びそれを使用する方法
US12618063B2 (en) Pan-genotypic agents against influenza virus and methods of using the same
Motard et al. A novel ribozyme-based prophylaxis inhibits influenza A virus replication and protects from severe disease
WO2025059148A1 (en) Agents against respiratory viruses and methods of using the same
Giannecchini et al. Packaging signals in the 5′-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules
HK40118855A (en) Pan-genotypic agents against respiratory viruses and methods of using the same
HK40091735A (en) Pan-genotypic agents against respiratory viruses and methods of using the same
HK40113249A (en) Pan-genotypic agents against influenza virus and methods of using the same
Hagey et al. Identification and targeting of a pan-genotypic influenza A virus RNA structure that mediates packaging and disease
HK1262033A1 (en) Pan-genotypic agents against influenza virus and methods of using the same
Diefenbacher Dissecting mechanisms of intersegment epistasis and its role in influenza A virus biology.
Perez Molecular Evolution of Human H3N2 Influenza A Viruses During Adaptation to the Swine Host
Zhu Host Genes Defend Against Influenza a Virus: SNHG15, IFITS and PARP14
WO2018140354A1 (en) Antisense oligonucleotides that inhibit influenza virus replication and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260403

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260430

R150 Certificate of patent or registration of utility model

Ref document number: 7863883

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150